Response to Interferon-Free Direct Antivirals (DAAS) Treatment in Hcv-Related Subcutaneous Marginal Zone B-Cell Lymphoma with Lipoma-Like Presentation: Report of Two Cases

• Published in: Mediterranean journal of hematology and infectious diseases 2019-09, Vol.11 (1)
• Main Authors: De Luca, Maria Lucia, Lombardi, Laura, Tartaglia, Germana, Fazio, Francesca, Di Prima, Alessio, Serrao, Alessandra, Canichella, Martina, Pulsoni, Alessandro
• Format: Article
• Language: English
• Subjects: Case Report
• ISSN: 2035-3006
• DOI: 10.4084/MJHID.2019.053

Many epidemiological, biological and therapeutic studies have extensively investigated the etiological link between HCV infection and B-cell Non-Hodgkin Lymphoma (NHL). Large experiences in the literature demonstrated HCV-related indolent NHL regression after antiviral therapy. While the response to interferon-ribavirin-based antiviral therapy is well documented, evidence of the efficacy of interferon-free Direct-Acting Antivirals (DAAs) in this subset of lymphoma is also currently increasing. Splenic and Nodal Marginal zone Lymphoma (MZL) are frequently associated with HCV chronic infection. In this article we report two cases of HCV-related MZL with an unusual presentation, subcutaneous “lipoma-like” nodules, treated with DAAs. Both patients, a 59-years-old woman and a 72-years-old man, were affected by HCV chronic infection since several years and were referred to our Institute for a diagnosis of MZL with subcutaneous presentation. Given the possible etiological link with HCV infection, both patients were treated with DAAS. A Sustained virological response (SVR) was reached after few weeks of therapy and at the end of treatment a clinically and radiologically documented reduction of MZL localizations, persisting to date, were obtained in both patients. The two clinical cases presented in this article confirm the efficacy of DAA’s as first-line treatment in HCV related NHL, also in this rare entity of MZL with subcutaneous presentation.